SU596165A3 - Способ получени имидазолидинов - Google Patents

Способ получени имидазолидинов

Info

Publication number
SU596165A3
SU596165A3 SU762414002A SU2414002A SU596165A3 SU 596165 A3 SU596165 A3 SU 596165A3 SU 762414002 A SU762414002 A SU 762414002A SU 2414002 A SU2414002 A SU 2414002A SU 596165 A3 SU596165 A3 SU 596165A3
Authority
SU
USSR - Soviet Union
Prior art keywords
preparing
imidazolidine
solvent
trifluoromethyl
imidaealidines
Prior art date
Application number
SU762414002A
Other languages
English (en)
Inventor
Перронне Жак
Жиро Пьер
Бонне Клод
Original Assignee
Руссель-Юклаф (Фирма)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Руссель-Юклаф (Фирма) filed Critical Руссель-Юклаф (Фирма)
Application granted granted Critical
Publication of SU596165A3 publication Critical patent/SU596165A3/ru
Priority to MD94-0279A priority Critical patent/MD246C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Electromechanical Clocks (AREA)

Description

(54) СПОСОБ ПОЛУЧЕНИЯ ИМИДАЭОЛИДИНОВ
Пример 2. 1-(3-трифторметил-4 нитрофенил )-4,4-диметил-имидазолин-2 ,5-дион.
К 35 f«i водного раствора сол ной кислоты () и 35 мл воды прибавл ют 10 г 1-(3-трифторметил-4-нитрофе-нил )-4,4-диметил-5-иминоимилазолин-2-она , сусйензию нагревают с обратным холодильником 1 ч, Jpxлaждaют до и выливают в воду . Образовавшийс  осадок фильтруют, промывают, сушат и получают 9,5 г целевого продукта,т.пл. 149-С. После перекристаллизации из этанола т.пл. та же.
Найдено,%: С 45,5; Н 3,4; Р 17,9; Л12,9.
,FS Nj р
Вычислено %:С 45,43;Н 3,17,Р 17,96; Н13,24.
В ИК-спектре (хлороформ) наблюдаютс  характеристические полосы поглощени  (CMJ ) при 3438 {.NH), 1792 и 1734 (С«О), 1597 и 1501 ( ароматическое  дро ) , 1545, 1358 и 1349 (NO).

Claims (2)

  1. Формула изобретени  1. Способ получени  имидаэалидинов общей формула
    где X - кислород или иминна  труппа, отличающийс  тем, что 2-амино-2-цианпропан подвергают .взаимодействию с З-трифторметил-4-нитрофениловым эфиром изоциановой кислоты в присутствии третичного амина, в среде органичесл ого растворител  и полученное соединение выдел ют или подвергают гидролизу в кислой среде.
  2. 2. Способ по п, 1 о т л и ч а ющ и и с   тем, что в качестве растворител  примен ют тетрагидрофуран.
    Источники информации, прин тые во внимание при экспертизе:
    1. Райд К. Курс физической органи .ческой химии. М., 1972, с.456.
SU762414002A 1975-10-29 1976-10-21 Способ получени имидазолидинов SU596165A3 (ru)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MD94-0279A MD246C2 (ru) 1975-10-29 1994-09-08 Способ получения имидазолидинов

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7533084A FR2329276A1 (fr) 1975-10-29 1975-10-29 Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant

Publications (1)

Publication Number Publication Date
SU596165A3 true SU596165A3 (ru) 1978-02-28

Family

ID=9161795

Family Applications (1)

Application Number Title Priority Date Filing Date
SU762414002A SU596165A3 (ru) 1975-10-29 1976-10-21 Способ получени имидазолидинов

Country Status (18)

Country Link
US (1) US4097578A (ru)
JP (1) JPS6011701B2 (ru)
AU (1) AU500542B2 (ru)
BE (1) BE847742A (ru)
BG (1) BG60533B2 (ru)
CA (1) CA1086751A (ru)
CH (1) CH599164A5 (ru)
DE (1) DE2649925C2 (ru)
DK (1) DK152125C (ru)
ES (1) ES452746A1 (ru)
FR (1) FR2329276A1 (ru)
GB (1) GB1518444A (ru)
GE (1) GEP19970948B (ru)
IE (1) IE43875B1 (ru)
LU (2) LU76085A1 (ru)
NL (2) NL187102C (ru)
SE (1) SE430502B (ru)
SU (1) SU596165A3 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497812C2 (ru) * 2009-04-17 2013-11-10 Ипсен Фарма С.А.С. Производные имидазолидин-2,4-диона и их применение в качестве лекарственного средства против рака

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
IL55774A (en) * 1977-10-28 1982-04-30 Sparamedica Ag Pharmaceutical compositions containing urea derivatives,certain such novel derivatives and their manufacture
FI801184A7 (fi) * 1979-04-24 1981-01-01 F Hoffmann La Roche & Co Menetelmä imidatsolidiini-johdannaisten valmistamiseksi.
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
IE58836B1 (en) * 1984-08-02 1993-11-17 Labrie Fernand Pharmaceutical composition for combination therapy of hormone dependent cancers
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
IT1214735B (it) * 1986-11-04 1990-01-18 Roussel Maestretti Spa Impiego di 1-(3'-trifluorometil 4'nitrofenil) 4,4-dimetilimidazolin2,5-dione per il trattamento di cancri ormonodipendenti diverso da quello della prostata
US5084472A (en) * 1986-11-04 1992-01-28 Roussel Application of 1-(3'-trifluoromethyl-4'-nitrophenyl)-4,4'-dimethylimidazoline 2,5-dione in the treatment of hormone-dependent cancers other than that of the prostate
FR2619381B1 (fr) * 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) * 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) * 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US6002016A (en) * 1991-12-20 1999-12-14 Rhone-Poulenc Agrochimie Fungicidal 2-imidazolin-5-ones and 2-imidazoline-5-thiones
FR2706456B1 (fr) * 1993-06-18 1996-06-28 Rhone Poulenc Agrochimie Dérivés optiquement actifs de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
FR2685328B1 (fr) * 1991-12-20 1995-12-01 Rhone Poulenc Agrochimie Derives de 2-imidazoline-5-ones et 2-imidazoline-5-thiones fongicides.
FR2694290B1 (fr) * 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US6008370A (en) * 1992-11-25 1999-12-28 Rhone-Poulenc Agrochimie Fungicidal-2-alkoxy/haloalkoxy-1-(mono- or disubstituted)amino-4,4-disubstituted-2-imidazolin-5-ones
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2725206B1 (fr) * 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
MXPA02012605A (es) * 2000-06-28 2003-05-14 Squibb Bristol Myers Co Moduladores selectivos del receptor androgeno y metodo para su identificacion, dise°o y uso.
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2003005889A2 (en) * 2001-07-10 2003-01-23 Ams Research Corporation Surgical kit for treating prostate tissue
US7087636B2 (en) 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7354933B2 (en) * 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MXPA06001751A (es) * 2003-08-22 2006-05-12 Ligand Pharm Inc Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno.
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
ATE502298T1 (de) * 2003-12-19 2011-04-15 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
CA2579514A1 (en) * 2004-09-10 2006-03-23 Janssen Pharmaceutica N.V. Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms)
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
BRPI0609191B8 (pt) * 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US9232959B2 (en) 2007-01-02 2016-01-12 Aquabeam, Llc Multi fluid tissue resection methods and devices
EP3510959B1 (en) 2007-01-02 2021-03-03 AquaBeam LLC Minimally invasive devices for the treatment of prostate diseases
US12290277B2 (en) 2007-01-02 2025-05-06 Aquabeam, Llc Tissue resection with pressure sensing
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
JP5506702B2 (ja) 2008-03-06 2014-05-28 アクアビーム エルエルシー 流体流れ内を伝達される光学エネルギーによる組織切除および焼灼
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US9848904B2 (en) 2009-03-06 2017-12-26 Procept Biorobotics Corporation Tissue resection and treatment with shedding pulses
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CN108606773B (zh) 2012-02-29 2020-08-11 普罗赛普特生物机器人公司 自动化图像引导的组织切除和处理
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2945628T3 (pl) 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
JP6403695B2 (ja) 2013-02-14 2018-10-10 プロセプト バイオロボティクス コーポレイション アクアアブレーションアクアビーム眼科手術方法および装置
EP3696276A1 (en) 2013-02-25 2020-08-19 Novartis AG Novel androgen receptor mutation
BR112016005036A2 (en) 2013-09-06 2020-04-07 Procept Biorobotics Corporation automated image guided tissue resection device
BR112016031037B1 (pt) 2014-06-30 2023-02-07 Procept Biorobotics Corporation Aparelho para ablação de tecido vascular
BR112017004431B1 (pt) 2014-09-05 2022-11-01 Procept Biorobotics Corporation Aparelho para tratar um paciente
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CA3036011A1 (en) 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
CN107216290B (zh) * 2017-06-12 2021-03-16 陕西科技大学 一种3-丁基-5,5-二甲基海因咪唑季铵盐及其制备方法
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020214834A1 (en) 2019-04-19 2020-10-22 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB997037A (en) * 1962-03-19 1965-06-30 Ici Ltd New hydrantoin derivatives
JPS4920973B1 (ru) * 1970-05-28 1974-05-29
JPS5136332B1 (ru) * 1970-12-09 1976-10-07
IL45459A (en) * 1973-09-03 1978-01-31 Ciba Geigy Ag 1-(dichlorofluoromethylthio)-3-phenyl-imidazolidine-2,4-dione derivatives their preparation and their use as bactericides and fungicides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2497812C2 (ru) * 2009-04-17 2013-11-10 Ипсен Фарма С.А.С. Производные имидазолидин-2,4-диона и их применение в качестве лекарственного средства против рака
US8710091B2 (en) 2009-04-17 2014-04-29 Ipsen Pharma S.A.S. Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug

Also Published As

Publication number Publication date
ES452746A1 (es) 1977-10-01
US4097578A (en) 1978-06-27
DE2649925C2 (de) 1986-08-28
NL930079I2 (nl) 1993-10-01
BG60533B2 (bg) 1995-07-28
SE7610859L (sv) 1977-04-30
NL187102B (nl) 1991-01-02
IE43875B1 (en) 1981-06-17
DE2649925A1 (de) 1977-05-12
CH599164A5 (ru) 1978-05-12
GEP19970948B (en) 1997-04-18
JPS5257176A (en) 1977-05-11
DK152125B (da) 1988-02-01
NL7611576A (nl) 1977-05-03
GB1518444A (en) 1978-07-19
JPS6011701B2 (ja) 1985-03-27
CA1086751A (fr) 1980-09-30
NL187102C (nl) 1991-06-03
AU1909576A (en) 1978-05-04
FR2329276B1 (ru) 1979-09-14
NL930079I1 (nl) 1993-09-16
DK152125C (da) 1988-06-20
LU76085A1 (ru) 1977-05-31
IE43875L (en) 1977-04-29
AU500542B2 (en) 1979-05-24
FR2329276A1 (fr) 1977-05-27
BE847742A (fr) 1977-04-28
DK487476A (da) 1977-04-30
SE430502B (sv) 1983-11-21
LU88282I2 (fr) 1994-05-04

Similar Documents

Publication Publication Date Title
SU596165A3 (ru) Способ получени имидазолидинов
ATE1192T1 (de) Verfahren zur herstellung von beta-lactam-derivaten, die so erhaltenen neuen derivate sowie diese derivate enthaltende pharmazeutische zusammensetzungen.
US4093653A (en) Process for the preparation of optically active phenyl glycine amide
DE2322576A1 (de) Antibiotische derivate und verfahren zu deren herstellung
SU612626A3 (ru) Способ получени 3-(3,5-дихлорфенил)гидантоина
US3901915A (en) Optical resolution of organic carboxylic acids
ATE169292T1 (de) Verfahren zur herstellung von 5-carbamoyl-5h- dibenz-(b,f>-azepin
EP0051816B1 (de) Basisch substituierte 5-Phenyltetrazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Heilmittel
ATE43585T1 (de) Neue imidazolylverbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
SU530022A1 (ru) Способ получени гидразидов аминокислот
CH473821A (de) Verfahren zur Herstellung von Iminodibenzyl-Derivaten
NO741143L (no) Fremgangsmåte ved fremstilling av aminosyreamider av dopamin.
EP0056970A1 (de) Basisch substituierte Anthranilsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
SU598871A1 (ru) Способ получени гидрохлорида метиламиноацетопирокатехина
US2785183A (en) N [4-aminopyrrolyl-2-carbonyl] amino acids
SU487886A1 (ru) Способ получени 1- -хлоргексилкарбамоилбензимидазолин-2-карбаматов
SU1245573A1 (ru) Способ получени 5-алкил- @ -карбэтоксиметил-2-пирролидонов
EP0025859A3 (de) Verfahren zur Herstellung von 1,2,4-Triazolen
SU437290A1 (ru) Способ получени рацемических или оптически активных производных пиперазина
SU979339A1 (ru) Способ получени 2-амино-3,4-дициано-1,5-замещенных пирролов
SU478833A1 (ru) Способ получени производных тиено -(3,2-в)-пиррола
SU667130A3 (ru) Способ получени соли лизина и -метил-(изопропил-2-инданил-5) уксусной кислоты
DE1470020C (de) alpha Hydrazino beta (5 hydroxy 3 indolyl) propionsäure und Verfahren zu ihrer Herstellung
AT400146B (de) Verfahren zur herstellung von 1-(2-((5-
SU479768A1 (ru) Способ получени производных пиримидина